Pulmonary Fibrosis Treatment Market Size & Share, by Drug (Pirfenidone and Nintedanib) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Risk Factors Associated With Pulmonary Fibrosis to Drive the Market Growth
  There are certain risk factors which lead to the occurrence of pulmonary fibrosis. These include geriatric population, smoking, exposure to toxins, cancer treatments along with some genetic factors. According to the National Health Service (NHS) in UK, idiopathic pulmonary fibrosis (IPF) commonly affects people between the ages of 70 and 75 years, and it rarely occurs among people under the age of 50 years. Moreover, it states that about 1 in 20 people with IPF have a family history of the disease. These risk factors are estimated to drive the pulmonary fibrosis treatment market growth in coming years. 
• Increase in Cigarette Smoking Population to Drive the Market Growth
  The increasing number of people who smoke is a major concern which results in several diseases of the lungs, including pulmonary fibrosis. According to Centers for Disease Prevention and Control, around 13.7% of all adults, i.e., 34.2 million people were reported to smoke cigarettes in the United States in 2018, out of which, 15.6% were men and 12.0% were women. This is predicted to raise the demand for drugs for pulmonary fibrosis and thereby boost the growth of the pulmonary fibrosis treatment market during the forecast period.

Challenges

• Limited Availability of Approved Drugs to Restrict the Market Growth
  Presently, only a few drugs have been received approval by the FDA and other regulatory bodies for the treatment of pulmonary fibrosis. There are only two approved drugs as of now, pirfenidone and nintedanib. This is estimated to limit the market growth. More research and development in the field is required in order to expand the pulmonary fibrosis treatment market size.